Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIP Study of Pemziviptadil in PAH
NCT03556020Phase 2Terminated
- Sponsor
- PhaseBio Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Jan 2022
- Modality
- Peptides, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pemziviptadil in pulmonary arterial hypertension (PAH), sponsored by PhaseBio Pharmaceuticals. Primary endpoints: Incidence and severity of Adverse Events at 172 days and Change in Pulmonary Vascular Resistance at 16 weeks. Started Jul 2018; status: terminated.
02
Drugs
pemziviptadil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03556020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03556020.